Key result
High CardTox-Score is linked to ~6-fold higher cardiotoxicity risk with non-anthracycline chemotherapy.
Why the study?
Sufficient prediction of chemotherapy-induced myocardial toxicity in cancer patients undergoing non-anthracycline chemotherapy is desirable but lacking.
Does the CardTox-Score predict the development of chemotherapy-induced myocardial toxicity in cancer patients undergoing non-anthracycline chemotherapy?
Comparison
CardTox-Score risk assessment vs no risk score
Design
Prospective cohort study with internal validation, single-blind
Authors
Loading...
May support pre-treatment risk stratification in non-anthracycline regimens; hypothesis-generating pending prospective validation.
Cohort (n=255)
Single-blind
No
Does the CardTox-Score predict the development of chemotherapy-induced myocardial toxicity in cancer patients undergoing non-anthracycline chemotherapy?
Odds Ratio: 6.38 (95% CI 1.21–33.52)
p-value: p=<0.001
The CardTox-Score is a feasible and highly predictive tool for estimating the risk of chemotherapy-induced myocardial toxicity and all-cause mortality in patients receiving non-anthracycline regimens.
Öztürk et al. (2021) conducted a cohort in Cancer patients undergoing non-anthracycline chemotherapy (n=255). CardTox-Score > 6 points vs. CardTox-Score ≤ 6 points was evaluated on Development of chemotherapy-induced myocardiotoxicity (CIMC) (OR 6.38, 95% CI 1.21-33.52, p=<0.001). A CardTox-Score >6 points strongly predicted the development of chemotherapy-induced myocardiotoxicity in cancer patients undergoing non-anthracycline regimens (OR 6.38).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: